Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16555563 | 0.79 | PDE2A (0.31) | — | |
| SCHEMBL16555495 | 0.79 | RECQL (0.34) | — | |
| SCHEMBL19866089 | 0.78 | CA12 (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL30856816 | 0.78 | CA12 (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL16825617 | 0.78 | ALDH1A1 (0.40) | ALDH1A1KDM4ERXFP1SMN1; SMN2NPSR1 | |
| SCHEMBL16680707 | 0.78 | TRPV4 (0.39) | ALDH1A1KDM4ERXFP1NPSR1KMT2A | |
| SCHEMBL12147468 | 0.77 | ALDH1A1 (0.41) | ALDH1A1KDM4ERXFP1SMN1; SMN2NPSR1 | |
| SCHEMBL16555544 | 0.76 | ALDH1A1 (0.35) | ALDH1A1KDM4ERXFP1SMN1; SMN2NPSR1 | |
| SCHEMBL16555771 | 0.75 | TRPV4 (0.33) | ALDH1A1KDM4ERXFP1SMN1; SMN2NPSR1 | |
| SCHEMBL846222 | 0.73 | ALDH1A1 (0.41) | ALDH1A1KDM4ERXFP1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083639-B1 | CYCLIC SULFONE AND SULFOXIMINE ANALOGS AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2019-05-29 | — | — | EP | disclosed |
| US-10098878-B2 | HIF-2α inhibitors for treating iron overload disorders | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-10-16 | — | — | US | disclosed |
| US-9884843-B2 | Cyclic sulfone and sulfoximine analogs and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170304300-A1 | HIF-2alpha INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-26 | — | — | US | disclosed |
| US-9796697-B2 | Tricyclic inhibitors of HIF-2-alpha and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3203991-A1 | HIF-2 INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS | The Board of Regents of The University of Texas System (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20160368893-A1 | CYCLIC SULFONE AND SULFOXIMINE ANALOGS AND USES THEREOF | Peloton Therapeutics ,Inc. | 2016-12-22 | — | — | US | disclosed |
| US-20160362390-A1 | TRICYCLIC INHIBITORS OF HIF-2-ALPHA AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2016-12-15 | — | — | US | disclosed |
| EP-3083639-A1 | CYCLIC SULFONE AND SULFOXIMINE ANALOGS AND USES THEREOF | Peloton Therapeutics, Inc. (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2016057242-A1 | HIF-2α INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2015095048-A1 | CYCLIC SULFONE AND SULFOXIMINE ANALOGS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304300-A1 | HIF-2alpha INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS | HIF1AN, HIF1A, EGLN2 | ALDH1A1 1260/4885KDM4E 1205/4885RXFP1 386/4885 |
| US-10098878-B2 | HIF-2α inhibitors for treating iron overload disorders | HIF1AN, HIF1A, EGLN2 | ALDH1A1 1136/4885KDM4E 1423/4885RXFP1 331/4885 |
| US-20160368893-A1 | CYCLIC SULFONE AND SULFOXIMINE ANALOGS AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | ALDH1A1 1476/4885KDM4E 1078/4885RXFP1 2350/4885 |
| US-20160362390-A1 | TRICYCLIC INHIBITORS OF HIF-2-ALPHA AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | ALDH1A1 1090/4885KDM4E 1698/4885RXFP1 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.